UCB Aims High In Hidradenitis Suppurativa After Bimzelx Success
Set To Challenge Humira In Skin Disease
Executive Summary
Topline results from two Phase III studies show the Belgian group's dual IL-17A and IL-17F inhibitor met its primary and secondary endpoints ahead of a filing for hidradenitis suppurativa next year. How well it compares with Humira and Cosentyx in this indication remains to be seen, however.